ImmunityBio Inc. (NASDAQ:IBRX) is one of the best high growth healthcare stocks to buy now. On March 24, the FDA posted a warning letter to its site, stating that its Office of Prescription Drug Promotion “reviewed the promotional communications, a direct-to-consumer broadcast advertisement submitted by ImmunityBio Inc. (NASDAQ:IBRX), under cover of Form FDA 2253 and a DTC podcast titled, ‘Is the FDA BLOCKING Life Saving Cancer Treatments?’ regarding Anktiva…”. It added that complaints were received by the FDA Bad Ad Program regarding promotional communications for Anktiva, and the FDA determined that “the TV ad and podcast are false or misleading.
Reuters reported the same day that ImmunityBio Inc. has been directed by the FDA to cease the TV ad and podcast or take it down, and also submit a written response within 15 working days addressing the concerns described in the letter. The company told Reuters in an email that the process of reviewing the agency’s letter has begun, and it aims to respond within the requested timeframe to address the matter.
ImmunityBio, Inc. is a clinical-stage immunotherapy company that develops next-generation therapies to treat cancer and infectious diseases. Its immunotherapy platform activates the adaptive and innate immune systems to create long-term immunological memory.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
